

Pharmaceutical and Therapeutics (P&T) Committee

Iowa Medicaid P & T Committee Meeting

November 20, 2025

Hybrid Meeting

Location: Lucas State Office Building
Ground Floor, Assembly Room LG20-B
321 E 12th Street
Des Moines, IA 50319

Time: 9:30 a.m. – 4:30 p.m.

Teams Meeting: [Join the meeting now](#)
Meeting ID: 253 780 260 851 6
Passcode: Cx7oP363

Tentative Agenda

1. Welcome & Introductions
 - a) Committee Members and Staff
2. Committee Business
 - a) Approval of the open session minutes
 - b) Annual Conflict of Interest Disclosure
 - c) Conflict of Interest Disclosure
3. Update
 - a) Preferred Drug List (PDL) – Reference Iowa Medicaid PDL Revision Notifications
 - b) Medicaid Drug Rebate Issues
 - c) Prior Authorization Criteria/Pro-DUR edits – Reference Informational Letters and DUR Recommendations
 - d) Legislation
 - e) Iowa Medicaid Updates
4. Public Comment (**See attachment 1 for Conflict of Interest Disclosure**)
 - Verbal - Must pre-register to provide verbal public comment and submit a completed conflict of interest disclosure. Must indicate if will be in-person or virtual testimony. Five (5) minute maximum limit.
 - Written - Must submit written comments and a completed conflict of interest disclosure.
 - **All submissions must be received no later than 4:00 p.m. CT November 12, 2025.**
 - Send to pba_iapdlinfo@optum.com. **Indicate in email if providing written or verbal comment.**

5. Closed Executive Session - *Motion to go into closed session pursuant to Iowa Code section 21.5(1)(a), to review and discuss closed-session items which are required or authorized by federal law to be kept confidential.*
 - a) Approval of the closed session minutes
 - b) Confidential Economic Review of the Iowa Medicaid PDL, Newly Released Drugs, Newly Released Generic Drugs, New Dosage Forms, and Contracts
 - c) Review and discussion of the Confidential Public Comments

RETURN TO OPEN SESSION

6. PDL discussion and deliberation
(See attachment 2 and 3 for order of discussion)
7. Final Recommendations by the P & T Committee on the Iowa Medicaid PDL (Open Session)
8. Review of Newly Released Drugs
(See attachment 4 for order of discussion)
9. Final Recommendations by the P & T Committee on Newly Released Drugs (Open Session)
10. Review of Newly Released Generic Drugs, Dosage Forms or Strengths
(See attachment 5 for order of discussion)
11. Final Recommendations by the P & T Committee on Newly Released Generic Drugs, Dosage Forms or Strengths (Open Session)
12. Staff presentation
 - a) High Cost Drugs Review
13. Preview of next meeting
14. Adjournment

****Disclaimer: Closed Executive Sessions may be necessary during the deliberation process****

www.iowaMedicaidPDL.com

Next scheduled meeting: April 16, 2026 9:30am - 2:30pm

For more information contact Erin Halverson at erin.halverson@hhs.iowa.gov or (515) 974-3126

Iowa Medicaid Pharmaceutical and Therapeutics (P&T) Committee Public Comment Conflict of Interest Disclosure

The Iowa Medicaid Pharmaceutical and Therapeutics (P&T) Committee and persons speaking or providing written comment to the Iowa Medicaid P&T Committee are asked to disclose to the Committee any financial or other affiliation with organizations that may have a direct or indirect interest in the business. Those persons providing public comment to the P&T Committee meetings are asked to disclose potential conflicts on this form. P&T Committee members disclose potential conflicts each year on a separate form.

A financial interest may include, but is not limited to, being a shareholder in the organization, being on retainer with the organization, having research or honoraria paid by the organization, or receiving other forms of remuneration from an organization. An affiliation may include holding a position on an advisory committee or some other role or benefit to a supporting organization.

The existence of such financial relationships or affiliation does not necessarily constitute a conflict of interest and will not preclude an individual from participating or addressing the P&T Committee. This policy is intended to openly identify any potential conflicts so that the P&T Committee members and the public are able to form their own judgments.

Please indicate type of public comment:

- ☐ **Verbal Comment, presented in person (option only for hybrid meetings)**
- ☐ **Verbal Comment, presented virtually (option for hybrid and virtual meetings)**
- ☐ **Written Comment**

Your responses below will be read out loud before your verbal presentation or supplied with your written comment to the P&T Committee.

Please check the box of the statement that best applies.

- ☐ **Statement of No Conflicts**
I do not have a current or recent (within the last 12 months) financial arrangement or affiliation with any organization that may have a direct interest in the business before the Iowa Medicaid P&T Committee.
- ☐ **Disclosures**
I do have a financial interest, affiliation or am employed by an organization that may have a direct interest in the business before the Iowa Medicaid P&T Committee
- ☐ **I refuse to state my affiliation(s)**

Organization (List additional on the back of the form.)	Role/Relationship (List additional on the back of the form.)

(print name)

(signature)

(date)

Attachment 2

Iowa Medicaid Preferred Drug List

Disclaimer: The Iowa P&T Committee reserves the right to re-evaluate all medications within the same therapeutic category as those on the agenda scheduled to be discussed for the PDL Review, New Drug Review, New Generic Drug Review, and New Dosage Forms Review and vote to change the PDL status of other medications currently on the PDL. It is the responsibility of the drug manufacturer to provide representation, if necessary, at the P&T Committee Meeting when a competitor's product is on the agenda for discussion.

- 1) ACE and Thiazide Combo's
- 2) ACE Inhibitors
- 3) ACE Inhibitors and CA Channel Blockers
- 4) Achondroplasia Treatments
- 5) Acne Products: Isotretinoin
- 6) Agents for Fabrys Disease
- 7) Agents for Gaucher Disease
- 8) Agents for Pheochromocytoma
- 9) Alcohol Deterrents
- 10) Allergenic Extracts
- 11) Alpha-Proteinase Inhibitor
- 12) ALS Drug
- 13) Alzheimer – Cholinomimetics
- 14) Amino Glycosides
- 15) Amyloidosis Treatments
- 16) Analgesics – Misc.
- 17) Anaphylaxis Therapy
- 18) Androgens / Anabolics
- 19) Androgens-Topical
- 20) Anorectal – Misc.
- 21) Anthelmintics
- 22) Anti-Infective Combo's – Misc.
- 23) Antianginals
- 24) Antianginals – Isosorbide Nitrate
- 25) Antiarrhythmics
- 26) Antiasthmatic – 5-Lipoxygenase Inhibitors
- 27) Antiasthmatic – Adrenergic Combos
- 28) Antiasthmatic – Anti-Cholinergics
- 29) Antiasthmatic – Anti-Inflammatory Agents
- 30) Antiasthmatic – Beta-Adrenergics
- 31) Antiasthmatic – Leukotriene Receptor Antagonists
- 32) Antiasthmatic – Misc. Respiratory Inhalants
- 33) Antiasthmatic – Mixed Adrenergics
- 34) Antiasthmatic – Mucolytics
- 35) Antiasthmatic – Nasal Misc.

- 36) Antiasthmatic – Steroid Inhalants
- 37) Antiasthmatic – Xanthines
- 38) Antibiotics – Misc.
- 39) Anti-Cataleptic Agents
- 40) Anticoagulants
- 41) Anticonvulsants
- 42) Antidepressants- MAO Inhibitors
- 43) Antidepressants- Selected SSRI'S
- 44) Antidepressants- SNRI's
- 45) Antidepressants- Tri-Cyclics
- 46) Antidepressants- MISC
- 47) Antidepressants- Serotonin Modulators
- 48) Antidotes
- 49) Antidotes – Chelating Agents
- 50) Antiemetic – 5-HT₃ Receptor Antagonists/Substance P Neurokinin
- 51) Antiemetic – Anticholinergic / Dopaminergic
- 52) Antiemetic – Tetrahydrocannabinol (THC) Derivatives
- 53) Antifungals – Assorted
- 54) Antihemophilia Factor IX Agents
- 55) Antihemophilia Factor VII Agents
- 56) Antihemophilia Factor VIII Agents
- 57) Antihemophilia Factor VonWillebrand Agents
- 58) Antihemophilia Factor X Agents
- 59) Antihemophilic Agents
- 60) Antihistamines – Non-Sedating
- 61) Antihistamines – Non-Sedating / Decongestants
- 62) Antihistamines – Other
- 63) Antihyperlipidemics
- 64) Antihypertensives – Central
- 65) Anti-IGE & Interleukin Antibodies
- 66) Anti-Inflammatories, Non-NSAID
- 67) Antileprotic
- 68) Antimalarial Agents
- 69) Antimycobacterials / Antituberculosis
- 70) Anti-Parkinsonian Drugs
- 71) Antiprotozoal Agents
- 72) Anti-Psoriatics – Non-Biologicals
- 73) Antipsychotics- Atypicals
- 74) Antipsychotics- Special Atypicals
- 75) Antipsychotics- Typical
- 76) Antispasmodics
- 77) Antispasmodics – Long Acting
- 78) Anti-Thrombocytopenics
- 79) Antithyroid Therapies
- 80) Anxiolytics-Benzodiazepines
- 81) Anxiolytics- Long Acting

- 82) Anxiolytics- Misc.
- 83) ARB Combinations
- 84) ARB/CCB
- 85) ARB/CCB Plus Diuretics
- 86) ARB's
- 87) ARB's and Diuretics
- 88) Arthritis – Misc.
- 89) Artificial Saliva / Stimulants
- 90) Atopic Dermatitis
- 91) Beta Blockers – Alpha / Beta
- 92) Beta Blockers – Cardio Selective
- 93) Beta Blockers – Non-Selective
- 94) Beta Blockers and Diuretic Combo's
- 95) Beta – Lactams / Clavulanate Combo's
- 96) BPH
- 97) Calcium Channel Blockers – Amlodipines
- 98) Calcium Channel Blockers – Diltiazems
- 99) Calcium Channel Blockers – Felodipines
- 100) Calcium Channel Blockers – Isradipines
- 101) Calcium Channel Blockers – Nifedipines
- 102) Calcium Channel Blockers – Nisoldipine
- 103) Calcium Channel Blockers – Verapamils
- 104) Carbapenems
- 105) Cardiac Glycosides
- 106) Cardiovascular Agents
- 107) Carnitine Replenisher – Agents
- 108) CCB / Lipid
- 109) Central Nervous System Agents
- 110) Cephalosporins
- 111) CGRP Inhibitors
- 112) Chelating Agents
- 113) Cholesterol – Bile Sequestrants
- 114) Cholesterol – Fibric Acid Derivatives
- 115) Cholesterol – HMG COA + Absorb Inhibitors
- 116) Cholesterol – HMG COA + Absorb Inhibitors: High Potency
Drugs/Combinations
- 117) Cholesterol – HMG COA + Absorb Inhibitors: Low Potency Drugs/Combinations
- 118) Cholinergic
- 119) Complement Inhibitors
- 120) Compounding Materials
- 121) Contraceptives – Emergency Contraceptives
- 122) Contraceptives – Injectable
- 123) Contraceptives – Monophasic Combination O/C's
- 124) Contraceptives – Multi-Phasic Combinations
- 125) Contraceptives – Patches / Vaginal Products
- 126) Contraceptives – Progestin Only

- 127) Contraceptives – Tri-Phasic Combinations
- 128) Cough / Cold – Antitussive – Expectorant
- 129) Cough / Cold – Systemic Decongestants
- 130) COVID-19 Agents
- 131) Cox 2 Inhibitors – Selective
- 132) Cushings Disease Treatments
- 133) Cystic Fibrosis Agents
- 134) Cyto-Megalovirus Agents
- 135) Dental Products
- 136) Diabetic – Alphaglucosidase
- 137) Diabetic – Insulin
- 138) Diabetic – Insulin Penfills
- 139) Diabetic – Meglitinides
- 140) Diabetic – Oral Biguanides
- 141) Diabetic – Oral Sulfonylureas
- 142) Diabetic – Other
- 143) Diabetic – Sulfonylurea / Biguanide
- 144) Diabetic – Thiazol
- 145) Diabetic – Thiazol / Biguanide Combo
- 146) Diabetic Amylin Analogs
- 147) Diabetic- DPP-4 Inhibitor Combinations
- 148) Diabetic- GIP/GLP-1 Receptor Agonists
- 149) Diabetic- GLP-1 Receptor Agonists
- 150) Diabetic- Insulin Combinations
- 151) Diabetic- SGLT2 Inhibitor Combinations
- 152) Diabetic- Sodium-Glucose Co-Transporter (SGLT2) Inhibitors
- 153) Direct Renin Inhibitors
- 154) Diuretics
- 155) Dopamine Receptor Agonists
- 156) Ear
- 157) Electrolytes / Nutritionals
- 158) Endocrine Metabolic Agents
- 159) Endometriosis Agents
- 160) Endothelin and Angiotensin II Receptor Antagonists
- 161) Erythropoiesis Stimulating Agents
- 162) Estrogen Combo's
- 163) Estrogens – Patches
- 164) Estrogens – Tabs
- 165) Fluoroquinolones
- 166) GI – Anti-Flatulents / GI Stimulants
- 167) GI – Antidiarrheal / Antacid – Misc.
- 168) GI – Antiperistaltic Agents
- 169) GI – Digestive Enzymes
- 170) GI – H2-Antagonists
- 171) GI – Inflammatory Bowel Agents
- 172) GI – Irritable Bowel Syndrome Agents

- 173) GI – Misc.
- 174) GI – Misc. Anti-Ulcer
- 175) GI – Prostaglandins
- 176) GI – Proton Pump Inhibitor
- 177) GI – Proton Pump Inhibitor / NSAID Combo
- 178) GI – Ulcer Anti-Infective
- 179) GI, Constipation-IBS-OIC
- 180) Glucocorticoids – Corticotropin
- 181) Glucocorticoids – Mineralocorticoids
- 182) Gout
- 183) Granulocyte CSF
- 184) Growth Hormone
- 185) Heart Failure Agents
- 186) Hematopoietic Agents
- 187) Hemostatic
- 188) Hepatitis B Only
- 189) Hepatitis C Agents
- 190) Hereditary Angioedema Agents
- 191) Hereditary Tyrosinemia Type 1 (HT-1) Treatment – Agents
- 192) Herpes Agents
- 193) Hormone Receptor Modulators
- 194) Hyperparathyroid Treatment – Vitamin D Analogs
- 195) Hyperparathyroid Treatment – Vitamin D Analogs and Calcimimetics
- 196) Idiopathic Pulmonary Fibrosis
- 197) Immune Serums
- 198) Immunosuppressants
- 199) Influenza Agents
- 200) Interferon Gamma
- 201) K Removing Resins
- 202) Lincosamides / Oxazolidinones / Leprostatics
- 203) Lipodystrophy Agents
- 204) Lithium
- 205) Macrolides / Erythromycin's / Ketolides
- 206) Migraine – Ergotamine Combinations
- 207) Migraine – Ergotamine Derivatives
- 208) Migraine – Selective Serotonin Agonists (5HT) – Injectables
- 209) Migraine – Selective Serotonin Agonists (5HT) – Tabs
- 210) Migraine-Selective Serotonin Agonist-(5HT) Combinations
- 211) Mineralocorticoid – Receptor Antagonists
- 212) Minerals
- 213) Mouth – Anesthetics Topical Oral
- 214) Mouth – Steroids
- 215) Mouth Anti-Infectives
- 216) Mouth Antiseptics
- 217) Multiple Sclerosis Agents
- 218) Multiple Sclerosis Agents-Interferons

219) Multiple Sclerosis Agents-Non-Interferons
220) Muscle Relaxants
221) Muscular Atrophy Agents
222) Narcotic – Antagonists
223) Narcotics – Misc.
224) Narcotics – Selected
225) Narcotics – Long Acting
226) Nasal Steroid/Antihistamine Combos
227) Nasal Steroids
228) Neurologics – Misc.
229) Nicardipines
230) Nicotine Replacement Therapy
231) Nitro – Ointment / Cap / CR
232) Nitro – Patches
233) Nitro – Sublingual / Spray
234) NSAIDS
235) Op. Antiallergics-Antihistamines
236) Op. Antiallergics-Mast Cell Stabilizers
237) Op. Antibiotics
238) Op. Antiinflammatory / Steroids Ophth
239) Op. Beta-Blockers
240) Op. Carbonic Anhydrase Inhibitors / Combo
241) Op. Cycloplegics
242) Op. Miotics – Direct Acting
243) Op. Misc.
244) Op. NSAID's
245) Op. Prostaglandins
246) Op. Quinolones
247) Op. Quinolones-Fourth Generation
248) Op. Rho Kinase Inhibitors
249) Op. Selective Alpha Adrenergic Agonists
250) Opioid Withdrawal Treatments
251) Osteoporosis
252) Oxytocics
253) Parkinsons – Anticholinergics
254) Parkinsons – COMT Inhibitors
255) Parkinsons – Selected Dopamine Agonists
256) Phenylketonuria
257) Phosphate Binders
258) Phosphodiesterase Inhibitors
259) Platelet Aggr. Inhibitors / Combo's – Misc.
260) Platelet Aggregation Inhibitors
261) Powders
262) Pressors
263) Progeria Treatments
264) Progestins

265) Psychotherapeutic Combination
266) Pulmonary Anti-Hypertensives
267) Pulmonary Anti-Hypertensives-Endothelin Receptor Antagonist
268) Purine Analog
269) Pyruvate Kinase Activators
270) Restless Leg Syndrome Agents
271) Rheumatoid Arthritis – Non-Biologicals
272) RSV Agents
273) Sedative / Hypnotics – Barbiturate
274) Sedative / Hypnotics – Benzodiazepines
275) Sedative / Hypnotics – Non-Benzodiazepines
276) SGLT 1/2 Inhibitors
277) Sick Cell Anemia Agents
278) Sinus Node Inhibitors
279) SLE Agents
280) Smoking Cessation (Oral)
281) Somatostatic Agents
282) Stimulants
283) Stimulants- Amphetamines- Long Acting
284) Stimulants- Amphetamines- Short Acting
285) Stimulants- Methylphenidate
286) Stimulants- Methylphenidate- Long Acting
287) Stimulants- Other Stimulants/ Like Stimulants
288) Tetracyclines
289) Thyroid Hormones
290) Tissue Plasminogen Activator
291) Topical – Acne Preparations
292) Topical – Antibiotic
293) Topical – Antifungals
294) Topical – Antineoplastics
295) Topical – Antipruritics
296) Topical – Antiseborrheics
297) Topical – Antivirals
298) Topical – Astringents / Protectants
299) Topical – Burn Products
300) Topical – Cauterizing Agents
301) Topical – Corticosteroids-High Potency
302) Topical – Corticosteroids-Low Potency
303) Topical – Corticosteroids-Medium Potency
304) Topical – Emollients
305) Topical – Enzymes / Keratolytics / Urea
306) Topical – Genital Warts
307) Topical – Immunomodulators
308) Topical – Local Anesthetics
309) Topical – Scabicides and Pediculicides
310) Topical – Steroid Combinations

- 311) Topical – Steroid Local Anesthetics
- 312) Topical – Tretinoids
- 313) Topical-Wound/Decubitus Care
- 314) Urea Cycle Disorder – Agents
- 315) Urological – Misc.
- 316) Vaginal – Antifungals
- 317) Vaginal – Antibacterials
- 318) Vaginal – Estrogens
- 319) Vasopressins
- 320) Vitamins
- 321) Vitamins – Misc.

Attachment 3

Iowa Medicaid Preferred Drug List Changes

The below changes are recommended to maximize cost savings to the program, unless otherwise noted:

1. Airsupra to Preferred
2. Breo Ellipta to Preferred
3. Trelegy Ellipta to Preferred
4. Sodium chloride solution neb 3% and 7% to Preferred
5. Dabigatran capsules to Preferred
6. Pradaxa capsules to Non-Preferred
7. Emend to Non-Preferred with Conditions
8. Diclegis to Non-Preferred
9. Doxylamine/pyridoxine to Preferred
10. Trimethobenzamide to Non-Preferred
11. Nucala prefilled syringe to Preferred with Conditions
12. Amjevita 40mg/0.4mL and 80mg/0.8mL to Non-Preferred with Conditions
13. Vtama to Preferred with Conditions
14. Rykindo to Non-Preferred Step 3
15. Caplyta to Preferred Step 2
16. Entresto tablets to Non-Preferred
17. Janumet XR to Non-Preferred with Conditions
18. Jentadueto XR to Preferred
19. Rybelsus to Preferred with Conditions
20. Exenatide to Preferred with Conditions
21. Pirfenidone to Preferred with Conditions
22. Austedo XR to Non-Preferred with Conditions
23. Nevanac to Non-Preferred
24. Ticagrelor to Preferred
25. Brilinta to Non-Preferred
26. Jornay PM to Preferred with Conditions
27. Spinosad topical suspension to Preferred

Attachment 4

Newly Released Drugs

Disclaimer: The Iowa P&T Committee reserves the right to re-evaluate all medications within the same therapeutic category as those on the agenda scheduled to be discussed for the PDL Review, New Drug Review, New Generic Drug Review, and New Dosage Forms Review and vote to change the PDL status of other medications currently on the PDL. It is the responsibility of the drug manufacturer to provide representation, if necessary, at the P & T Committee Meeting when a competitor's product is on the agenda for discussion.

1. Andembry – Recommend status on the PDL as Non-Preferred
2. Anzupgo- Recommend status on the PDL as Non-Preferred with Conditions ([JAK Inhibitors](#))
3. Brinsupri- Recommend status on the PDL as Non-Preferred
4. Harliku- Recommend status on the PDL as Non-Preferred
5. Hernexeos- Recommend status on the RDL as Non-Recommended with Conditions ([Select Oncology Agents](#))
6. Modeyso- Recommend status on the RDL as Non-Recommended with Conditions ([Select Oncology Agents](#))
7. Sephience- Recommend status on the as Non-Preferred
8. Tryptyr- Recommend status on the PDL as Non-Preferred
9. Vykat XR- Recommend status on the PDL as Non-Preferred
10. Wakix - Recommend status on the PDL as Non-Preferred with Conditions ([CNS Stimulants](#))
11. Yeztugo Tablets – Recommend status on the RDL as Non-Recommended
12. Zelsuvmi- Recommend status on the PDL as Non-Preferred
13. ZunveyI- Recommend status on the PDL as Non-Preferred

Attachment 5

Newly Released Generic Drugs, New Dosage Forms, New Drug Names, New Drug Strengths

Disclaimer: The Iowa P&T Committee reserves the right to re-evaluate all medications within the same therapeutic category as those on the agenda scheduled to be discussed for the PDL Review, New Drug Review, New Generic Drug Review, and New Dosage Forms Review and vote to change the PDL status of other medications currently on the PDL. It is the responsibility of the drug manufacturer to provide representation, if necessary, at the P&T Committee Meeting when a competitor's product is on the agenda for discussion.

NEWLY RELEASED GENERIC DRUGS		
Drug Name	Brand Name/Status on PDL/RDL	PDL/RDL Recommendation
Bosentan Soluble Tab	Tracleer Soluble Tab / Non-Preferred with Conditions	Non-Preferred with Conditions
Fidaxomicin	Dificid / Non-Preferred	Non-Preferred
Fluticasone Furoate	Arnuity Ellipta / Preferred	Non-Preferred
Pilocarpine 1.25% Ophth Solution	Vuity / Non-Preferred with Conditions	Non-Preferred with Conditions
Sacubitril-Valsartan	Entresto / Non-Preferred	Preferred
Topiramate Oral Solution	Eprontia / Non-Preferred with Conditions	Non-Preferred with Conditions

NEW DRUG DOSAGE FORMS/STRENGTHS/COMBINATIONS/BIOSIMILARS		
Drug Name	Brand Name/Status on PDL/RDL	PDL/RDL Recommendation
Brynovin Oral Solution	Januvia Tabs / Preferred	Non-Preferred with Conditions
Hydrocodone/Apap Oral Solution 10-300 MG	Hydrocodone/APAP Oral Solution 7.5-325 MG / Preferred	Non-Preferred with Conditions
Imuldosa	Stelara / Non-Preferred with Conditions	Non-Preferred with Conditions
Kirsty Vial & Pen	Insulin Aspart Vial & Pen / Preferred	Non-Preferred
Merilog	Insulin Aspart / Preferred	Non-Preferred
Merilog SoloStar	Insulin Aspart FlexPen / Preferred	Non-Preferred
Pruradik Lotion	Crotan / Non-Preferred	Non-Preferred